Journal of Dermatological Treatment This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Gabapentin and oral antidepressants for chronic pruritus: a prospective cohort study evaluating efficacy and side effects in daily dermatological practice
CONCLUSION: Treatment with gabapentin and antidepressants should be considered in patients with chronic pruritus unresponsive to conventional treatment.PMID:37905412 | DOI:10.1080/09546634.2023.2274291 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - October 31, 2023 Category: Dermatology Authors: T A Kouwenhoven P C M van de Kerkhof M Kamsteeg Source Type: research

Certolizumab treatment of localized pyoderma gangrenosum in a pregnant patient
CONCLUSION: Certolizumab may be a promising therapeutic option for patients with severe PG.PMID:37905433 | DOI:10.1080/09546634.2023.2276044 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - October 31, 2023 Category: Dermatology Authors: Na Wang Changping Yu Weiwei Wang Qing Yang Source Type: research

Patients with vulvar lichen sclerosus prioritize education on disease etiology, triggers and treatment
J Dermatolog Treat. 2023 Oct 30;34(1):2262632. doi: 10.1080/09546634.2023.2262632. Epub 2023 Oct 31.NO ABSTRACTPMID:37905436 | DOI:10.1080/09546634.2023.2262632 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - October 31, 2023 Category: Dermatology Authors: Emily A Parks Mallory L Zaino Jessica N Pixley Vani Mangalam Subramanian Deepak Sirdeshmukh Steven R Feldman Rita O Pichardo Source Type: research

Brodalumab for severe hidradenitis suppurativa: a case of clinico-radiologic improvement and literature review
We report the case of a 50-year-old man with long-standing HS and concomitant palmo-plantar psoriasis treated with brodalumab after failure of various TNF-α inhibitors. The HS lesions and the patient's quality of life improved steadily over time until week-136. Interestingly, the clinical benefit was confirmed by radiological improvement with MRI evaluation. Our case report demonstrates the long-term efficacy and safety of brodalumab in HS encouraging the use of drugs to inhibit the T helper-type 17 immune axis, especially in cases of HS refractory to therapy with TNF-α inhibitors.PMID:37842732 | DOI:10.1080/09546634.202...
Source: Journal of Dermatological Treatment - October 16, 2023 Category: Dermatology Authors: Emanuele Vagnozzi Manfredo Bruni Maria Esposito Maria Concetta Fargnoli Source Type: research